BVT receives first patent approval for its proprietary microbial strain
Bee Vectoring Technologies has received patent allowance for its microbial strain Clonostachys rosea strain BVT CR-7, granted in the United States. This patent allowance protects a critical component of BVT’s proprietary vectoring technology.
This is the first patent granted to BVT for its CR-7 microbial strain, representing the start of a fourth family of granted patents in BVT’s expanding patent portfolio. This patent application is under review by 15 other patent authorities around the world, including the European Patent Office.
“This is a milestone patent protecting our proven CR-7 fungal strain and recognizes its unique properties as a plant beneficial microbe including the biological control of various plant diseases,” stated Ashish Malik, President and CEO of BVT. “This patent protects our CR-7 product, independent of its use as a biologic control agent vectored by bees. It enables BVT to concurrently develop revenue streams for CR-7 use in foliar sprays and seed treatments, in a well-established traditional global fungicide market.”